Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monogram's new HER assays available for clinical trials

This article was originally published in Clinica

Executive Summary

Monogram Biosciences has launched two assays for use in clinical trials of cancer drugs, including those for breast cancer. The first quantifies levels of the HER2:HER3 heterodimer, while the second analyses HER3:PI3K, an associated downstream complex. An assay for p95, a truncated form of HER2, is in "advanced development". The San Francisco, California firm launched its HER2 assay, HERmark, in the US in July (see Clinica No 1315, p 17). This identifies patients who will respond to HER2-targeting therapies like Roche's Herceptin (trastuzumab). Herceptin inhibition could be mediated by the PI3K pathway, and PI3K signalling could also be implicated in other cancers. Earlier this month, UK firm DxS launched its PIK3CA gene test for use in cancer clinical trials (see Clinica No 1327, p 29).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel